Tvardi Therapeutics, Inc. TVRD
1.41 USD 0.00 (+0.00%)
At closeNov 10, 2026, 6:27 PM EST
1.42 +0.01 +0.71%
After hours · Nov 10, 6:27 PM ET
1.31 Day range 1.52
0.773 52-week range 5.69
- YTD
- -67.21%
- 1 year
- -66.35%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
benzinga.com Chardan Capital Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $8 Chardan Capital analyst Gautam Chukka initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $8.
globenewswire.com Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
defenseworld.net Head-To-Head Survey: Tvardi Therapeutics (NASDAQ:TVRD) versus Phibro Animal Health (NASDAQ:PAHC) Tvardi Therapeutics (NASDAQ: TVRD - Get Free Report) and Phibro Animal Health (NASDAQ: PAHC - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen…
benzinga.com Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciences In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and…
globenewswire.com New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC) In a preclinical chronic colitis model, Tvardi's oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and…
globenewswire.com Tvardi Therapeutics to Participate in Upcoming Investor Events HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule…
seekingalpha.com Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2…
benzinga.com Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by 1.43 percent. This is a 31 percent increase over losses of…
globenewswire.com Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations- benzinga.com Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UC Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to
globenewswire.com Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral,…
benzinga.com BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5 BTIG analyst Julian Harrison maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and lowers the price target from $15 to $5.
globenewswire.com Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences…
zacks.com TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
benzinga.com Why Is Tvardi Therapeutics Stock Falling Thursday? Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
benzinga.com Raymond James Upgrades Tvardi Therapeutics to Outperform, Announces $10 Price Target Raymond James analyst Ryan Deschner upgrades Tvardi Therapeutics (NASDAQ:TVRD) from Market Perform to Outperform and announces $10 price target.
seekingalpha.com Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript Tvardi Therapeutics, Inc. (TVRD) Discusses Phase 1 Data on TTI-109 STAT3 Inhibitor Highlighting Prodrug Design, Tolerability and Target Engagement Transcript
benzinga.com Why Is Tvardi Therapeutics Stock Gaining Tuesday? Tvardi Therapeutics (TVRD) stock jumps 50% after reporting positive Phase 1 data for its next-gen STAT3 inhibitor, TTI-109. Read more.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics…
benzinga.com BTIG Reiterates Buy on Tvardi Therapeutics, Maintains $15 Price Target BTIG analyst Julian Harrison reiterates Tvardi Therapeutics (NASDAQ:TVRD) with a Buy and maintains $15 price target.
benzinga.com Tvardi Therapeutics Announces Phase 1 Results For TTI-109, Next-Gen STAT3 Inhibitor; Co. Plans To Advance TTI-109 Into STAT3-Driven Dermatologic And Gastrointestinal Diseases, Subject To Additional Funding TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh)…
globenewswire.com Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh)…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday's regular session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
benzinga.com Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announcing acquisition of Best Praise International for $10.75 million.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
benzinga.com This Cerebras Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Analysts think CBRS stock is a buy.
benzinga.com HC Wainwright & Co. Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $9 HC Wainwright & Co. analyst Sara Nik initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $9.
globenewswire.com Tvardi Therapeutics to Participate in Upcoming Investor Events HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule…- benzinga.com Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 77.33 percent increase over losses of…
globenewswire.com Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in…- benzinga.com Tvardi Therapeutics Files Prospectus For Offering $200M Mixed Shelf https://www.sec.gov/Archives/edgar/data/1346830/000110465926054113/tm2613101-1_s3.htm
defenseworld.net Brokerages Set Tvardi Therapeutics, Inc. (NASDAQ:TVRD) PT at $55.50 Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company,…- benzinga.com Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3 Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.
globenewswire.com Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule…- benzinga.com Barclays Maintains Equal-Weight on Tvardi Therapeutics, Lowers Price Target to $4 Barclays analyst Etzer Darout maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Equal-Weight and lowers the price target from $5 to $4.
- benzinga.com Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3 Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral and lowers the price target from $4 to $3.
benzinga.com Tvardi Therapeutics Q4 EPS $(0.78) Misses $(0.68) Estimate Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.68) by 15.38 percent. This is a 84.21 percent increase over losses…
globenewswire.com Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in…
defenseworld.net Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average PT from Analysts Shares of Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat Ratings…
globenewswire.com Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentation Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium…